Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | -0.11 | 0.00 | -0.00 |
| FCF Yield | -126.98% | -17,527.68% | -29,246.73% | -20,572.74% |
| EV / EBITDA | -1.11 | -325.10 | -0.17 | 2.64 |
| Quality | ||||
| ROIC | -178.82% | -0.11% | 59.97% | -33.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.91 | 0.73 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 33.26% | -86.34% | 3.07% | -74.76% |
| Safety | ||||
| Net Debt / EBITDA | -0.48 | -318.44 | -0.16 | 2.65 |
| Interest Coverage | -21.09 | -28.03 | 121,137.82 | -1.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -311.82 | 0.00 | -52.56 | -380.68 |